RecruitingPhase 2NCT05344833

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Illinois at Chicago
Intervention
Isatuximab(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
2023 – 2030

Study locations (2)

Collaborators

Huntsman Cancer Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05344833 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials